Endogenous cannabinoid and vanilloid receptor agonist, in water-soluble emulsion (for details see TocrisolveTM 100
, Cat. No. 1684). Ki
values are 89 and 371 nM for CB1
receptors respectively; EC50
values are 18, 31 and 27 nM at GPR55, CB1
= 5.68 for rVR1. Also blocks TNF-α
-induced NF-kB activation via direct inhibition of IKK. Also available as the pure oil dissolved in ethanol (Anandamine
, Cat. No. 1339). Tocrisolve Control
(Cat. No. 1684) also available.
Store at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
The orphan receptor GPR55 is a novel cannabinoid receptor.
Ryberg et al.
Pharmacology of cannabinoid receptor ligands.
Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross et al.
Anandamide inhibits nuclear factor-κB activation through a cannabinoid receptor-independent pathway.
Sancho et al.
Complex regional haemodynamic effects of anandamide in conscious rats.
Gardiner et al.
Characterization of the anandamide-induced depolarization of guinea-pig isolated vagus nerve.
Kagaya et al.
The citations listed below are publications that use Tocris products. Selected citations for Anandamide (in Tocrisolve™ 100) include:
Showing Results 1 - 5 of 5